Endeavor

Moffitt Uses Innovative Immunotherapy to Stand Up To (Lung) Cancer

The unique clinical trial combining two immunotherapies is funding by the Stand Up To Cancer Catalyst® Program.

A New Drug Could Soon Be Available to Treat a Common Form of Skin Cancer

Nearly half of the patients who participated in the trial saw their tumors shrink.

Small Cell Lung Cancer Patients Who Have Failed Previous Therapies Now Have New Hope — the First in 20 Years

New drug allows your T cells to go to work, destroying cancer.

CAR T Drives New Ovarian Cancer Research

The new genetically-modified CAR T-cells seek out and destroy cancer cells expressing an FSH receptor protein found on a large number of ovarian cancer cells.

Father’s Cancer Battle Inspires Son’s Research

Moffitt Physician Co-Led Pivotal Study of CAR-T Therapy

CAR T Provides Remission, Purpose for Moffitt Leukemia Patient

For CAR T treatment, T cells are removed from a patient’s blood and sent to a lab where the cells are genetically modified to better enable them to identify and attack cancer cells.

FDA Approves Second CAR T Therapy for Diffuse Large B-Cell Lymphoma

Moffitt Cancer Center is the only center in Florida to offer both FDA approved CAR T therapies, Kymriah™ and Yescarta™

Ovarian Cancer Patients May Benefit from Personalized Vaccines

Could personalized vaccines be the future of ovarian cancer treatment?

Immunotherapy Key to Unlocking Lung Cancer Survival

A recent study represents another step forward in immunotherapy, which has been making steady gains in recent years.